Travis Murdoch, HI-Bio CEO
ARCH-backed immunology company HI-Bio raises $95M as it pushes toward late-stage studies
Human Immunology Biosciences, known as HI-Bio for short, has raised $95 million as it awaits data from a series of studies on its lead compound …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
